Risk of depression and dementia among individuals treated with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.

IF 7.5 2区 医学 Q1 PSYCHIATRY
Osvaldo P Almeida
{"title":"Risk of depression and dementia among individuals treated with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.","authors":"Osvaldo P Almeida","doi":"10.1097/YCO.0000000000001001","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of the review: </strong>To review whether sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists decrease the risk of depression, suicidal ideation and cognitive impairment in later life.</p><p><strong>Recent findings: </strong>The results of studies using information derived from large registries and administrative health datasets suggest that GLP-1 receptor agonists (RAs) increase the risk of suicidality, although findings have been inconsistent. One nested-case control study reported that SGLT2i decreases the risk of depression among adults with diabetes, and findings from a small trial of the SGLT2i empagliflozin provided supportive evidence. Several observational studies reported that SGLT2i and GLP-1 RAs decrease dementia risk, with a target trial finding greater cognitive benefit associated with the use of GLP-1 RAs compared with other medicines commonly used to manage diabetes.</p><p><strong>Summary: </strong>Recent results from large observational studies suggest that SGLT2i and GLP-1 RA may decrease the risk of cognitive impairment in later life. The effects of these medicines on mood have not been as well explored, but there are concerns about the potential increased risk of suicidality among GLP-1 RA users. Prescription bias could explain some of these associations, so that robust trial evidence is now needed to confirm or dismiss the reported findings.</p>","PeriodicalId":11022,"journal":{"name":"Current Opinion in Psychiatry","volume":" ","pages":""},"PeriodicalIF":7.5000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/YCO.0000000000001001","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of the review: To review whether sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists decrease the risk of depression, suicidal ideation and cognitive impairment in later life.

Recent findings: The results of studies using information derived from large registries and administrative health datasets suggest that GLP-1 receptor agonists (RAs) increase the risk of suicidality, although findings have been inconsistent. One nested-case control study reported that SGLT2i decreases the risk of depression among adults with diabetes, and findings from a small trial of the SGLT2i empagliflozin provided supportive evidence. Several observational studies reported that SGLT2i and GLP-1 RAs decrease dementia risk, with a target trial finding greater cognitive benefit associated with the use of GLP-1 RAs compared with other medicines commonly used to manage diabetes.

Summary: Recent results from large observational studies suggest that SGLT2i and GLP-1 RA may decrease the risk of cognitive impairment in later life. The effects of these medicines on mood have not been as well explored, but there are concerns about the potential increased risk of suicidality among GLP-1 RA users. Prescription bias could explain some of these associations, so that robust trial evidence is now needed to confirm or dismiss the reported findings.

接受钠-葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂治疗的个体抑郁和痴呆的风险
综述的目的:回顾钠-葡萄糖共转运蛋白2 (SGLT2)抑制剂和胰高血糖素样肽-1 (GLP-1)受体激动剂是否能降低晚年抑郁、自杀意念和认知障碍的风险。最近的研究结果:使用来自大型登记处和行政卫生数据集的信息的研究结果表明,GLP-1受体激动剂(RAs)增加自杀风险,尽管研究结果不一致。一项巢式病例对照研究报告称,SGLT2i降低了成人糖尿病患者患抑郁症的风险,一项关于SGLT2i恩格列净的小型试验的结果提供了支持性证据。几项观察性研究报告称,SGLT2i和GLP-1 RAs可降低痴呆风险,一项目标试验发现,与其他常用的糖尿病治疗药物相比,使用GLP-1 RAs可获得更大的认知益处。摘要:最近大型观察性研究的结果表明,SGLT2i和GLP-1 RA可能会降低晚年认知障碍的风险。这些药物对情绪的影响还没有得到很好的研究,但人们担心GLP-1 RA使用者的自杀风险可能会增加。处方偏倚可以解释其中的一些关联,因此现在需要强有力的试验证据来证实或驳回报告的发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Opinion in Psychiatry
Current Opinion in Psychiatry 医学-精神病学
CiteScore
12.20
自引率
1.40%
发文量
76
审稿时长
6-12 weeks
期刊介绍: Current Opinion in Psychiatry is an easy-to-digest bimonthly journal covering the most interesting and important advances in the field of psychiatry. Eight sections on mental health disorders including schizophrenia, neurodevelopmental disorders and eating disorders, are presented alongside five area-specific sections, offering an expert evaluation on the most exciting developments in the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信